This suggests that, after developing resistance to ALK-TKIs, ivonescimab may serve as a potential therapeutic option for NSCLC patients who are ALK fusion–positive, have high PD-L1 expression, and carry a BIM deletion polymorphism. This evidence concerns the gene BCL2L11 and non-small cell lung carcinoma.